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ABSTRACT 
Dengue is an arthropod-borne infectious disease caused by dengue 
virus (DENV) infection and transmitted by Aedes mosquitoes. 
Approximately 50–100 million people are infected with DENV each 
year, resulting in a high economic burden on both governments and 
individuals. The prevalence is increasing across South East Asia, 
Africa, America and Western Pacific. DENV infection results in a 
broad spectrum of clinical symptoms, ranging from mild fever to DHF, 
and then progress to DSS and death. The pathophysiological 
parameters for the early recognition of plasma leakage and appropriate 
fluid therapy. 
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INTRODUCTION 
Dengue is a mosquito borne disease belong to the Flaviviridae family, caused by any one of 
four closely related dengue viruses (DENV- 1, -2, -3 and -4). Infection with one serotype of 
DENV provides immunity to that serotype for life, but provides no long-term immunity to 
other serotype.
[1,2] There are 4 serotypes of DENV (DENV-1 through DENV-4) that cause 




Dengue Fever (DF) can be with or without   hemorrhage, while Dengue Hemorrhagic Fever 
DHF can be with or without shock, that is called Dengue Shock Syndrome.
[3] The WHO 
criteria for the clinical diagnosis of Dengue Hemorrhage Fever (DHF) requires the presence 
of acute and continuous fever of 2 to 7 days, haemo-concentration (hematocrit >20% from 
baseline of patient) and the manifestation of hemorrhagic associated with thrombocytopenia 
(100.000 cells/c.mm or less). Hemorrhagic manifestations could be skin or mucosal or even a 
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Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) is endemic in tropical and 
subtropical zones and the prevalence is increasing across South-east Asia, the western 
Pacific, the Americas and Africa. There are more 100 dengue endemic countries in the world. 
In Asia, dengue fever (DF) and dengue hemorrhagic fever (DHF) affect mainly in children 
under 15 years old.
[5] Approximately 2.5   billion people are at risk of dengue infection every 
year. It estimated 390 million dengue infection every year, of which 96 million manifests 
apparently any level of disease severity. In America, 2.35 million cases of dengue were 





Today, dengue virus (DENV) poses a major threat to global public health, and approximately 
two-fifths of the world’s population is at risk of dengue infection.
[6,7] DHF has become a 
public health threat that is associated with remarkable morbidity and mortality, since the first 
outbreak was reported in 1779 in Jakarta, Indonesia.
[8] By the end of 2016, a total of 291,964 
outbreak-associated dengue cases had been reported in the literature, mainly from China 
(27.9%), Singapore (27.0%) and Malaysia (15.1%). The majority (72.4%) of dengue 
patients were reported in the Western Pacific region, followed by the American region 
(19.4%), Southeast Asia Region (4.8%), Eastern Mediterranean region (1.5%), European 





Figure 1: Global Dengue outbreaks distribution from 1990-2015 (Guo C, 2017). 
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MECHANISM 
Although DF and DHF are caused by the same virus, but there is a difference. The main 
difference is that hemoconcentration that can lead to shock condition. The shock is caused by 
plasma leak suspected because of the immunological process. In DF, this condition does        not 
occur. Clinical manifestation of DF starts when the virus enters the body. The virus will 
develop in the bloodstream and will be captured by macrophages. Viremia occurs 
immediately 2 days before the symptoms occur and end after five days of fever begins. 
Macrophages will immediately react by catching the virus and processing it so that the 
macrophages become APC (Antigen Presenting Cells). The antigen attached to this 
macrophage will activate T- Helper cells and attract other macrophages to phagocytes more 
viruses. T helper will activate T cytotoxic cells that will lyse macrophages that have 
phagocytes of the virus.
[9] 
The process causes the release of mediators that stimulate the 




PLASMA LEAKAGE IN DHF 
1. Pathophysiology 
In DHF there is no vasculitis and hence no injury to the vessel walls, and plasma leakage 
results from cytokine mediated increase in vascular permeability. The ensuing movement of 
albumin and the resultant reduction of intravascular oncotic pressure facilitate further loss of 
fluid from the intravascular compartment. The basic Starling principle still holds true in 
explaining microvascular ultrafiltration based on the balance of the oncotic and hydrostatic 
pressures. However, the glycocalyx which is a gelatinous layer lining the vascular endothelium 
is also implicated in controlling fluid movement by the adherence of albumin molecules in to 
its matrix, damage of which, leads to loss of albumin into the extravascular compartment. 





Dengue virus infection causes intense immune activation. Aberrant immune responses such 
as cytokine overproduction and generation of autoantibody acting against platelets and 
endothelial cells occur after dengue virus infection. A molecular mimicry between platelets 
or endothelial cells with the NS-1 or prM of dengue virus would explain the cross-reactive of 
antiNS1 or anti-prM antibody to host cells, and participate in the attack of platelet and 
endothelial cells during the disease development. Dengue virus could cause severe 
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hemophagocytic syndrome. High serum ferritin level, a macrophage activation marker in 
vivo, was found to be highly elevated in the dengue patients. This suggests that the 
monocytes or macrophages were activated by cytokines such as IFN-γ during the dengue 
disease process after dengue virus infection. The activated macrophages would then achieve 
the phagocytosis of the autoantibody-coated platelet and thus contribute to the development 
of thrombocytopenia in DHF/DSS. The anti-NS1 and anti-prM cross- reactive antibody to 
platelets and endothelial cells provide an explanation for the target specificity and unique 




3. Hemorrhagic Manifestation in DHF 
The pathogenesis of bleeding in DHF is unclear even though well-recognized coagulation 
disturbances do exist. The clinical hemorrhagic manifestations range from a mere positive 
tourniquet test, skin petechiae and ecchymoses to epistaxis, and gum bleeding to severe 
gastrointestinal hemorrhages. Thrombocytopenia is a consistent finding. These hematological 
abnormalities seem to correlate better with the timing and severity of plasma leakage rather 
than the clinical hemorrhagic manifestations.
[4]
 Hemorrhage contributes to dengue morbidity 
and mortality, especially during the severe thrombocytopenia and toxic hemorrhagic stage (3-5 
days after illness onset).
[11]
 Thrombocytopenia however correlates poorly with bleeding 
manifestations. Spontaneous bleeding been uncommon even with counts below 100,000 
cells/c.mm. It is strongly associated with the severity of vascular leakage. Counts below 
100,000 cells/c.mm or a rapid drop in the platelet count was associated with severe disease. 
 
TREATMENT OF DENGUE INFECTION IN ADULT 
There is no specific treatment for dengue. Early recognition of dengue fever like, bleeding 
and signs of circulatory collapse reduce mortality with dengue. Mild dengue infection may be 
treated with hydration and antipyretics.
[12] Agents like salicylates, non-steroidal anti-
inflammatory drugs and traditional medicine that can cause a hepatoxicity must be 
avoided.
[13] To identify the need for intravenous fluid therapy, circulation and vascular 
leakage must be monitored the value of pulse, blood pressure, hematocrit, urine output and skin 
perfusion. If shock persist, immediate volume replacement with Ringer’s Lactate, 






www.wjpr.net    │     Vol 10, Issue 14, 2021.      │     ISO 9001:2015 Certified Journal      │ 
 
 
Sugianto.                                                                             World Journal of Pharmaceutical Research 
222 
DISCUSSION 
Coagulopathy and plasma leakage are the fundamental pathological changes for clinical 
manifestations, mortality and morbidity in DHF. Plasma leakage progresses rapidly or slowly 
to cease completely and predictably after 24 to 48 hours of onset, raising the possibility of 
existence of underlying functional change rather than structural damage and inflammation in 
the vasculature. The two main fundamental pathological in DHF are plasma leakage and 
intrinsic coagulopathy. In plasma leakage, the balance of hydrostatic and oncotic pressures is 
important. The main factor implicated in the development of DHF rather than the relatively 
innocuous DF in dengue infection is secondary dengue infection but other factors like viral 
virulence and host characteristics are also important. Severe disease is the result of a complex 




Scientist and clinicians have increasingly the understanding of pathophysiology of DF and 
DHF from several perspective. Further studies are recommended to improve our knowledge 
of DHF pathogenesis, which is important for developing the effective therapeutic and vaccine 
against the DENV. 
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